WO2007059916A3 - Pharmaceutical composition - Google Patents

Pharmaceutical composition Download PDF

Info

Publication number
WO2007059916A3
WO2007059916A3 PCT/EP2006/011138 EP2006011138W WO2007059916A3 WO 2007059916 A3 WO2007059916 A3 WO 2007059916A3 EP 2006011138 W EP2006011138 W EP 2006011138W WO 2007059916 A3 WO2007059916 A3 WO 2007059916A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
pharmaceutical composition
present
lactamase inhibitor
novel
Prior art date
Application number
PCT/EP2006/011138
Other languages
French (fr)
Other versions
WO2007059916A2 (en
Inventor
Franz Xaver Schwarz
Original Assignee
Sandoz Ag
Franz Xaver Schwarz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag, Franz Xaver Schwarz filed Critical Sandoz Ag
Publication of WO2007059916A2 publication Critical patent/WO2007059916A2/en
Publication of WO2007059916A3 publication Critical patent/WO2007059916A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a novel solid dosage form comprising a β-lactam antibiotic and a β-lactamase inhibitor wherein the β-lactamase inhibitor is present in the film coating. The novel dosage form may be in a form of a coated tablet or multi- unit dosage form comprising coated particles.
PCT/EP2006/011138 2005-11-23 2006-11-21 Pharmaceutical composition WO2007059916A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SIP-200500321 2005-11-23
SI200500321 2005-11-23

Publications (2)

Publication Number Publication Date
WO2007059916A2 WO2007059916A2 (en) 2007-05-31
WO2007059916A3 true WO2007059916A3 (en) 2008-01-10

Family

ID=38015346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/011138 WO2007059916A2 (en) 2005-11-23 2006-11-21 Pharmaceutical composition

Country Status (1)

Country Link
WO (1) WO2007059916A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150238425A1 (en) 2012-08-28 2015-08-27 Dsm Sinochem Pharmaceuticals Netherlands B.V. Mini-tablets

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020946A1 (en) * 1994-02-04 1995-08-10 Smithkline Beecham Plc Bilayered amoxycillin tablets
WO1995028148A1 (en) * 1994-04-14 1995-10-26 Smithkline Beecham Plc Pharmaceutical formulation
EP1285649A1 (en) * 2001-08-23 2003-02-26 Cimex AG Bilayered dispersible tablet formulation comprising amoxycillin and clavulanate in separate layers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020946A1 (en) * 1994-02-04 1995-08-10 Smithkline Beecham Plc Bilayered amoxycillin tablets
WO1995028148A1 (en) * 1994-04-14 1995-10-26 Smithkline Beecham Plc Pharmaceutical formulation
EP1285649A1 (en) * 2001-08-23 2003-02-26 Cimex AG Bilayered dispersible tablet formulation comprising amoxycillin and clavulanate in separate layers

Also Published As

Publication number Publication date
WO2007059916A2 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
IL273332A (en) Modulators of atp-binding cassette transporters and pharmaceutical compositions containing the same
WO2007052121A3 (en) Multi-layered coating technology for taste masking
AU2002257587A1 (en) Novel medicament compositions on the basis of anticholinergics and PDE IV inhibitors
EP1905424A3 (en) Process for the preparation of a pharmaceutical composition comprising stabilized statin particles
GB2426007B (en) Water-based intermediate coating composition and method of forming multilayered coating film
WO2004071403A3 (en) Coated particles and pharmaceutical dosage forms
IL192640A0 (en) Inhibitors of tyrosine kinases and pharmaceutical compositions containing the same
WO2006004642A3 (en) Composition for coating of aluminum
ZA200809998B (en) Stable pharmaceutical composition containing docetaxel and a method of manufacturing the same
IL157326A0 (en) Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors
EP1988137A4 (en) Water-base coating composition and glasswork
EP4134366A4 (en) 3-azabicycloalkyl derivative and pharmaceutical composition containing same
AU2002356646A1 (en) Pharmaceutical compositions for the pulmonary delivery of aztreonam
AU2003280392A1 (en) Methods for coating substrates for pharmaceutical uses with a mixture of two film-forming coating agents
WO2007059916A3 (en) Pharmaceutical composition
AU2007310767A1 (en) New fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone HSP 90
EP2014629A3 (en) Materials for coating ceramic bodies, preparation and use thereof and ceramic bodies including the same
AU2003282375A1 (en) Pharmaceutical compositions and process of production thereof
WO2008068778A8 (en) Extended release pharmaceutical composition of pramipexole
WO2007052164A8 (en) A pharmaceutical formulation containing olanzapine
IL191992A0 (en) Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
WO2005039629A3 (en) Caspase inhibitors as coating materiel for medical products for inhibiting restenosis
EP3984529A4 (en) Timed-elution masking particles and oral pharmaceutical composition containing same
WO2007072060A3 (en) Particles comprising a core containing a hmg-coa reductase inhibitor and coated with a film
WO2007117648A3 (en) Lubricious coatings for pharmaceutical applications

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06818697

Country of ref document: EP

Kind code of ref document: A2